In regard with B7–H3, expression of this checkpoint on both differentiated cancer cells and CSCs with limited heterogeneity along with its expression on tumor vasculature and stroma and its restricted distribution among normal organs are all indicative of the importance of application of monoclonal antibodies (mAbs) against this glycoprotein for the sake of better control over TME and promoting a durable therapy [58]. Here, CD80 is linked to cancer.